210 related articles for article (PubMed ID: 27009930)
1. Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis.
Gonzalez Santiago TM; Wetter DA; Kalaaji AN; Limper AH; Lehman JS
Int J Dermatol; 2016 Aug; 55(8):823-30. PubMed ID: 27009930
[TBL] [Abstract][Full Text] [Related]
2. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions.
Lehman JS; Kalaaji AN
J Am Acad Dermatol; 2010 Nov; 63(5):815-23. PubMed ID: 20643496
[TBL] [Abstract][Full Text] [Related]
3. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive Treatment and Its Effect on the Occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila Infections/Colonizations Among Lung Transplant Recipients.
Wojarski J; Ochman M; Latos M; Biniszkiewicz P; Karolak W; Woźniak-Grygiel E; Maruszewski M; Urlik M; Mędrala W; Kułaczkowska Z; Pyrc K; Żegleń S
Transplant Proc; 2018 Sep; 50(7):2053-2058. PubMed ID: 30177108
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
7. Critical appraisal of the quality and content of clinical practice guidelines for pneumocystis jiroveci pneumonia (PJP) prophylaxis using the AGREE II instrument.
Yu Y; Yang H; Yu X; Hu X; Wang W; Yang X; Liu H; Ren L; Zhang X; Feng X; Liu L
J Clin Pharm Ther; 2020 Dec; 45(6):1325-1333. PubMed ID: 32710453
[TBL] [Abstract][Full Text] [Related]
8. [Pneumocystis pneumonia among patients with systemic diseases].
Khellaf M; Godeau B
Presse Med; 2009 Feb; 38(2):251-9. PubMed ID: 19062243
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered?
Okafor PN; Nunes DP; Farraye FA
Inflamm Bowel Dis; 2013 Jul; 19(8):1764-71. PubMed ID: 23615530
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.
Okafor PN; Farraye FA; Okafor AT; Erim DO
Dig Dis Sci; 2015 Dec; 60(12):3743-55. PubMed ID: 26177704
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study.
De Castro N; Neuville S; Sarfati C; Ribaud P; Derouin F; Gluckman E; Socié G; Molina JM
Bone Marrow Transplant; 2005 Nov; 36(10):879-83. PubMed ID: 16151423
[TBL] [Abstract][Full Text] [Related]
12. Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications.
Gerhart JL; Kalaaji AN
J Am Acad Dermatol; 2010 Jun; 62(6):957-61. PubMed ID: 19828210
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients.
Fillatre P; Decaux O; Jouneau S; Revest M; Gacouin A; Robert-Gangneux F; Fresnel A; Guiguen C; Le Tulzo Y; Jégo P; Tattevin P
Am J Med; 2014 Dec; 127(12):1242.e11-7. PubMed ID: 25058862
[TBL] [Abstract][Full Text] [Related]
14. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.
Cooley L; Dendle C; Wolf J; Teh BW; Chen SC; Boutlis C; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1350-63. PubMed ID: 25482745
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.
Yale SH; Limper AH
Mayo Clin Proc; 1996 Jan; 71(1):5-13. PubMed ID: 8538233
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Evaluation of Risk Factors for Pneumocystis jirovecii Pneumonia in Adult Solid Organ Transplant Recipients: A Systematic Review and Meta-analysis.
Permpalung N; Kittipibul V; Mekraksakit P; Rattanawong P; Nematollahi S; Zhang SX; Steinke SM
Transplantation; 2021 Oct; 105(10):2291-2306. PubMed ID: 33323766
[TBL] [Abstract][Full Text] [Related]
17. Balancing the risks and benefits of prophylaxis: a reply to "Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions".
Amber KT
Int J Dermatol; 2017 Jan; 56(1):e4-e5. PubMed ID: 27653175
[No Abstract] [Full Text] [Related]
18. [Pneumocystis jiroveci pneumonia in immunocompromised patients without AIDS -- a case series].
Blum T; Roth A; Mauch H; Erbes R; Lode H
Dtsch Med Wochenschr; 2006 Jul; 131(27):1515-20. PubMed ID: 16817100
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?
Stamp LK; Hurst M
J Rheumatol; 2010 Apr; 37(4):686-8. PubMed ID: 20360202
[No Abstract] [Full Text] [Related]
20. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study.
Chan SCW; Chung HY; Lau CS; Li PH
Ann Clin Microbiol Antimicrob; 2021 Nov; 20(1):78. PubMed ID: 34763703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
